Clinuvel Pharmaceuticals Limited (CLVLY) Financials
CLVLY Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2025 | 180.0 million | 13.8 million |
| June 30, 2025 | 178.7 million | 20.3 million |
| Dec. 31, 2024 | 146.8 million | 11.7 million |
| June 30, 2024 | 154.2 million | 18.8 million |
CLVLY Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2025 | 8.1 million | ? |
| June 30, 2025 | 18.2 million | ? |
| Dec. 31, 2024 | 8.1 million | 626938 |
| June 30, 2024 | 6.9 million | 309792 |
CLVLY Net Income
| Date | Net Income |
|---|---|
| Dec. 31, 2025 | 6.8 million |
| June 30, 2025 | 14.5 million |
| Dec. 31, 2024 | 8.7 million |
| June 30, 2024 | 16.5 million |
CLVLY Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2025 | 155.5 million | 23015 | 11507 |
| June 30, 2025 | 147.4 million | 64014 | 347567 |
| Dec. 31, 2024 | 123.2 million | 203028 | 444517 |
| June 30, 2024 | 122.7 million | 340308 | 587143 |
CLVLY Shares Outstanding
CLVLY Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2025 | 98002 | 2.2 million | 4.2 million | - |
| June 30, 2025 | 158292 | 3.0 million | 6.0 million | - |
| Dec. 31, 2024 | 35953 | 1.8 million | 8.0 million | 7.7 million |
| June 30, 2024 | 183304 | 1.1 million | 9.2 million | 8.6 million |
CLVLY Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2025 | 24.2 million | 10.6 million |
| June 30, 2025 | 39.0 million | 12.3 million |
| Dec. 31, 2024 | 22.2 million | 1.9 million |
| June 30, 2024 | 37.0 million | 3.5 million |
CLVLY
Price: $6.63
Dividend Yield: 0.45%
Forward Dividend Yield: 0.53%
Payout Ratio: 7.24%
Dividend Per Share: 0.03 USD
Earnings Per Share: 0.45 USD
P/E Ratio: 15.58
Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Country: Australia
Market Capitalization: 333.5 million
Average Dividend Frequency: 1
Years Paying Dividends: 8
DGR3: 7.22%
DGR5: 14.28%